Javascript must be enabled to continue!
Identify and Assess Drug Interactions with Atorvastatin in Inpatient Care
View through CrossRef
Background: Atorvastatin is a recent HMG-COA reductase inhibitor used to treat primary hypercholesterolemia, homozygous familial hypercholesterolemia, and mixed dyslipidemias. It is also taken to prevent heart disease, including strokes and heart attacks. In addition, Atorvastatin is used to lower bad cholesterol low-density lipoproteins (LDL) levels, increase good cholesterol high-density lipoprotein (HDL) levels, and lower triglycerides. It works by reducing the amount of cholesterol produced in the body, hence reducing the amount of cholesterol that may build up on the walls of arteries. Atorvastatin is long-acting, has few adverse effects, and is low in price. Nevertheless, it interacts with a wide variety of medications. These interactions may be lead to adverse drug reactions.
Objective: The study aims to identify and asset atorvastatin interactions with other medicines at King Abdulaziz Hospital. Also, to prevent atorvastatin interactions in the future.
Methods: The retrospective study investigated 280 electronic prescriptions inside the inpatient clinic at King Abdulaziz Hospital in Saudi Arabia between January and April 2021 to identify and asset interactions among atorvastatin and different medications.
Results: Most atorvastatin interactions are category C (44.64%) and category B (41.43%). Atorvastatin had the most common interactions with esomeprazole (16.07%), clopidogrel (14.64%), and sitagliptin (12.14%). Atorvastatin had clinical interactions with medications metabolized by the cytochrome P450 3A4 )CYP3A4(. Use of atorvastatin with cyclosporine or clarithromycin increased the risk for atorvastatin toxicities such as myopathy and rhabdomyolysis. In addition, Atorvastatin decreases clopidogrel's antiplatelet effect and increases the risk of skeletal muscle toxicity of daptomycin.
Conclusion: The majority of atorvastatin interactions may be avoided by adhering to best practices in clinical care and clinical pharmacology, such as avoiding complicated treatment regimens, utilizing a single pharmacy for all prescriptions, and recognizing patient risk factors. Health care professionals should use drug-drug interaction checkers such as Medscape and Micromedex, as well as a book such as the Handbook of Drug Interactions.
Sciencedomain International
Title: Identify and Assess Drug Interactions with Atorvastatin in Inpatient Care
Description:
Background: Atorvastatin is a recent HMG-COA reductase inhibitor used to treat primary hypercholesterolemia, homozygous familial hypercholesterolemia, and mixed dyslipidemias.
It is also taken to prevent heart disease, including strokes and heart attacks.
In addition, Atorvastatin is used to lower bad cholesterol low-density lipoproteins (LDL) levels, increase good cholesterol high-density lipoprotein (HDL) levels, and lower triglycerides.
It works by reducing the amount of cholesterol produced in the body, hence reducing the amount of cholesterol that may build up on the walls of arteries.
Atorvastatin is long-acting, has few adverse effects, and is low in price.
Nevertheless, it interacts with a wide variety of medications.
These interactions may be lead to adverse drug reactions.
Objective: The study aims to identify and asset atorvastatin interactions with other medicines at King Abdulaziz Hospital.
Also, to prevent atorvastatin interactions in the future.
Methods: The retrospective study investigated 280 electronic prescriptions inside the inpatient clinic at King Abdulaziz Hospital in Saudi Arabia between January and April 2021 to identify and asset interactions among atorvastatin and different medications.
Results: Most atorvastatin interactions are category C (44.
64%) and category B (41.
43%).
Atorvastatin had the most common interactions with esomeprazole (16.
07%), clopidogrel (14.
64%), and sitagliptin (12.
14%).
Atorvastatin had clinical interactions with medications metabolized by the cytochrome P450 3A4 )CYP3A4(.
Use of atorvastatin with cyclosporine or clarithromycin increased the risk for atorvastatin toxicities such as myopathy and rhabdomyolysis.
In addition, Atorvastatin decreases clopidogrel's antiplatelet effect and increases the risk of skeletal muscle toxicity of daptomycin.
Conclusion: The majority of atorvastatin interactions may be avoided by adhering to best practices in clinical care and clinical pharmacology, such as avoiding complicated treatment regimens, utilizing a single pharmacy for all prescriptions, and recognizing patient risk factors.
Health care professionals should use drug-drug interaction checkers such as Medscape and Micromedex, as well as a book such as the Handbook of Drug Interactions.
Related Results
Organisatie van geestelijke gezondheidszorg voor mensen met een ernstige en persisterende mentale aandoening
Organisatie van geestelijke gezondheidszorg voor mensen met een ernstige en persisterende mentale aandoening
1 INTRODUCTION AND RESEARCH QUESTIONS 5 -- 2 GENERAL BACKGROUND: DEFINITIONS AND SCOPE OF THE STUDY 7 -- 2.1 CHRONIC AND COMPLEX MENTAL DISORDERS: DEFINITIONS AND SCOPE OF THE -- S...
Profil Klinik dan Farmakoterapi Anti-Dislipidemia Diabetes di Rumah Sakit Gunawan Mangunkusumo Ambarawa
Profil Klinik dan Farmakoterapi Anti-Dislipidemia Diabetes di Rumah Sakit Gunawan Mangunkusumo Ambarawa
Dyslipidemia is characterized by increased plasma TG, low HDL-c, and high LDL-c, which is commonly found in patients with diabetes mellitus (DM) and is one of the main causes of is...
Combination of different drugs can enhance prevention of CIAKI through inhibition of endoplasmic reticulum stress-induced apoptotic pathway
Combination of different drugs can enhance prevention of CIAKI through inhibition of endoplasmic reticulum stress-induced apoptotic pathway
Abstract
Introduction: Contrast-induced acute kidney injury(CIAKI) is an important clinical complication that occurs after the application of contrast in percutaneous coron...
Atorvastatin promotes pro/anti-inflammatory phenotypic transformation of microglia via Wnt/β-catenin pathway in hypoxic-ischemic neonatal rats
Atorvastatin promotes pro/anti-inflammatory phenotypic transformation of microglia via Wnt/β-catenin pathway in hypoxic-ischemic neonatal rats
Abstract
Background
Inflammatory reaction plays a key role in the pathogenesis of hypoxic-ischemic encephalopathy (HIE) in neonates. Microglia are resident innate immune c...
e0034 Inhibition of atorvastatin on the autophagy of vascular endothelial cells
e0034 Inhibition of atorvastatin on the autophagy of vascular endothelial cells
Objective
To explore the mechanism of atorvastatin's protection on vascular endothelial cells, we conducted the research of impact of atorvastatin on vascular end...
Effects of atorvastatin on transient sodium currents in rat normal/simulated ischemia/reperfusion ventricular cell
Effects of atorvastatin on transient sodium currents in rat normal/simulated ischemia/reperfusion ventricular cell
Background
Some clinical trials have shown statins have anti-arrhythmic effects and can improve clinical results. But its mechanism is unclear.
...
The Effect of Liraglutide on the Hypolipidemic, Anti-Inflammatory, and Antioxidant Properties of Atorvastatin Mediated via the Nrf2/HO-1 Signaling Pathway: In Vivo and In Silico Validation
The Effect of Liraglutide on the Hypolipidemic, Anti-Inflammatory, and Antioxidant Properties of Atorvastatin Mediated via the Nrf2/HO-1 Signaling Pathway: In Vivo and In Silico Validation
Introduction: Oxidative stress and inflammation are major factors linked to obesity and metabolic dysfunction, leading to a significantly higher risk of related diseases. Atorvasta...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND
As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...

